Geoff Frampton: Evidence-based health technology and environmental research
Evidence Review Group reports for NICE and the NIHR Health Technology Assessment Programme
Report ( C - project coordinator, P - principal investigator, T - team contributor ) |
Link |
Role |
| Daratumumab combination therapy for newly-diagnosed multiple myeloma (2020) | C |
|
| Avapritinib for gastrointestinal stromal tumours (2020) | C |
|
| Emapalumab for treating primary haemophagocytic lymphohistiocytosis (2019-2020) | C |
|
| Dupilumab for treating severe asthma (2019) | T |
|
| Ustekinumab for treating moderately to severely active ulcerative colitis (2019) | C |
|
| Cemiplimab for treating squamous cell carcinoma (2018-2019) | C, P |
|
| Cabozantinib for untreated locally advanced or metastatic renal cell carcinoma (2018) | T |
|
| Tofacitinib for moderately to severely active ulcerative colitis (2018) | T |
|
| Daratumumab in combination with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (2018) | T |
|
| Ocrelizumab for treating relapsing multiple sclerosis (2018) | C |
|
| Atezolizumab after platinum chemotherapy, for treating urothelial, metastatic bladder cancer (2017) | C, P |
|
| Afamelanotide for treating erythropoietic protoporphyria (2017) | T |
|
| Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids (2016) | C |
|
| Migalastat for treating Fabry disease (2016) | C, P |
|
| Sofosbuvir for treating chronic hepatitis C (2016) | C, P |
|
| Cobimetinib in combination with vemurafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma (2016) | T |
|
| Necitumumab for untreated advanced, metastatic, squamous non-small-cell lung cancer (2016) | T |
|
| Nivolumab for treating advanced, untreated, unresectble, melanoma (2015) | T |
|
| Simeprevir for treating genotype 1 or 4 chronic heptitis (2014) | T |
|
| Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer (2012) | T |
|
| Aripiprazole for the treatment of schizophrenia in adolescents (aged 15-17 years) (2010) | T |
|
| Vinflunine for the second line treatment of transitional cell carcinoma of the urothelial tract | T |
|
| Entecavir for the treatment of chronic hepatitis B (2008) | T |
|